Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

19 Feb 2021

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare congenital disease that progresses through intermittent episodes of bone formation at ectopic sites. FOP patients carry heterozygous gene point mutations in activin A receptor type I ACVR1, encoding the bone morphogenetic protein (BMP) type I serine/threonine kinase receptor ALK2, termed activin receptor-like kinase (ALK)2. The mutant ALK2 displays...

Topics

Join the communities discussing this publication.

Heterotopic Ossification and Related Conditions
Medical Imaging and Pathology Studies
Parathyroid Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33669809
DOI: 10.3390/biomedicines9020213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaPMID 33669809Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

Clinical Aspects and Current Therapeutic Approaches for FOPSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Recent progress in drug development for fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.Semantic proximity Read ↗

The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva: a blueprint for metamorphosisSemantic proximity Read ↗

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.